Literature DB >> 2156599

Radiofrequency thermotherapy for malignant liver tumors.

Y Nagata1, M Hiraoka, K Akuta, M Abe, M Takahashi, S Jo, Y Nishimura, S Masunaga, M Fukuda, H Imura.   

Abstract

Inoperable malignant liver tumors have been treated by radiofrequency hyperthermia at Kyoto University Hospital since 1983. In this study, clinical hyperthermia for malignant liver tumor was evaluated for 67 tumors in which we could measure intratumor temperatures. Of the 67 tumors, 41 were hepatocellular carcinomas (HCC), six cholangiocarcinomas, and 20 metastatic tumors. Cholangiocarcinoma and metastatic tumors were more susceptible to this treatment than HCC. Of the three types of HCC, higher intratumor temperatures were achieved in the diffuse type than in the nodular or massive types. The minimum tumor temperature of HCC stayed below 40 degrees C in 46% of cases, especially in larger tumors. The local response rates (complete remission plus partial remission/all) were 28% and 11% for HCC and non-HCC, respectively, for thermochemotherapy; 86% and 33%, for thermoradiotherapy; and 33% and 89%, for thermotherapy with embolization. No apparent relationship was observed between the intratumor temperatures and local response rate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156599     DOI: 10.1002/1097-0142(19900415)65:8<1730::aid-cncr2820650812>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Nanoshell-mediated laser surgery simulation for prostate cancer treatment.

Authors:  Yusheng Feng; David Fuentes; Andrea Hawkins; Jon Bass; Marissa Nichole Rylander; Andrew Elliott; Anil Shetty; R Jason Stafford; J Tinsley Oden
Journal:  Eng Comput       Date:  2009       Impact factor: 7.963

2.  Successful treatment of a case of hepatocellular carcinoma with tumor necrosis factor and local hyperthermia.

Authors:  M Maeda; N Watanabe; N Yamauchi; Y Tsuji; Y Niitsu
Journal:  Gastroenterol Jpn       Date:  1991-12

3.  Non-Invasive Radiofrequency Field Treatment to Produce Hepatic Hyperthermia: Efficacy and Safety in Swine.

Authors:  Jason C Ho; Lam Nguyen; Justin J Law; Matthew J Ware; V Keshishian; N C Lara; Trac Nguyen; Steven A Curley; Stuart J Corr
Journal:  IEEE J Transl Eng Health Med       Date:  2017-04-03       Impact factor: 3.316

4.  Optimization and real-time control for laser treatment of heterogeneous soft tissues.

Authors:  Yusheng Feng; David Fuentes; Andrea Hawkins; Jon M Bass; Marissa Nichole Rylander
Journal:  Comput Methods Appl Mech Eng       Date:  2009       Impact factor: 6.756

5.  Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma.

Authors:  Kazutaka Kurokohchi; Seishiro Watanabe; Tsutomu Masaki; Naoki Hosomi; Yoshiaki Miyauchi; Takashi Himoto; Yasuhiko Kimura; Seiji Nakai; Akihiro Deguchi; Hirohito Yoneyama; Shuhei Yoshida; Shigeki Kuriyama
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

6.  Radiofrequency capacitive hyperthermia for unresectable hepatic cancers.

Authors:  K Yamamoto; Y Tanaka
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

7.  A combination therapy of ethanol injection and radiofrequency ablation under general anesthesia for the treatment of hepatocellular carcinoma.

Authors:  Kazutaka Kurokohchi; Seishiro Watanabe; Hirohito Yoneyama; Akihiro Deguchi; Tsutomu Masaki; Takashi Himoto; Hisaaki Miyoshi; Hamdy-Saad Mohammad; Akira Kitanaka; Tomohiko Taminato; Shigeki Kuriyama
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

8.  Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma.

Authors:  Naveen Kalra; Mandeep Kang; Ajay K Duseja; Anmol Bhatia; Virendra Singh; Radha K Dhiman; Arvind Rajwanshi; Yogesh K Chawla; Niranjan Khandelwal
Journal:  Indian J Med Res       Date:  2017-11       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.